Meyka Pro banner
Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. Fundamental Analysis (NASDAQ: ARQT)

ARQT●NASDAQ
HealthcareBiotechnology
$27.61
$0.28(1.02%)
U.S. Market opens in 2h 35m

Arcutis Biotherapeutics, Inc. Fundamental Analysis (NASDAQ: ARQT)

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) shows moderate financial fundamentals with a PE ratio of 118.13, profit margin of 5.88%, and ROE of 14.18%. The company generates $0.5B in annual revenue with strong year-over-year growth of 91.34%.

Key Strengths

PEG Ratio0.03
Current Ratio2.92

Areas of Concern

Operating Margin6.91%
We analyze ARQT's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 64.6/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.

Fundamental Health Score

C+
64.6/100

We analyze ARQT's fundamental strength across five key dimensions:

Efficiency Score

Weak

ARQT struggles to generate sufficient returns from assets.

ROA > 10%
5.70%

Valuation Score

Moderate

ARQT shows balanced valuation metrics.

PE < 25
118.13
PEG Ratio < 2
0.03

Growth Score

Excellent

ARQT delivers strong and consistent growth momentum.

Revenue Growth > 5%
91.34%
EPS Growth > 10%
88.79%

Financial Health Score

Excellent

ARQT maintains a strong and stable balance sheet.

Debt/Equity < 1
0.47
Current Ratio > 1
2.92

Profitability Score

Weak

ARQT struggles to sustain strong margins.

ROE > 15%
14.18%
Net Margin ≥ 15%
5.88%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is ARQT Expensive or Cheap?

P/E Ratio

ARQT trades at 118.13 times earnings. This suggests a premium valuation.

118.13

PEG Ratio

When adjusting for growth, ARQT's PEG of 0.03 indicates potential undervaluation.

0.03

Price to Book

The market values Arcutis Biotherapeutics, Inc. at 14.76 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

14.76

EV/EBITDA

Enterprise value stands at 75.74 times EBITDA. This signals the market has high growth expectations.

75.74

How Well Does ARQT Make Money?

Net Profit Margin

For every $100 in sales, Arcutis Biotherapeutics, Inc. keeps $5.88 as profit after all expenses.

5.88%

Operating Margin

Core operations generate 6.91 in profit for every $100 in revenue, before interest and taxes.

6.91%

ROE

Management delivers $14.18 in profit for every $100 of shareholder equity.

14.18%

ROA

Arcutis Biotherapeutics, Inc. generates $5.70 in profit for every $100 in assets, demonstrating efficient asset deployment.

5.70%

Following the Money - Real Cash Generation

Operating Cash Flow

Arcutis Biotherapeutics, Inc. produces operating cash flow of $57.88M, showing steady but balanced cash generation.

$57.88M

Free Cash Flow

Arcutis Biotherapeutics, Inc. generates strong free cash flow of $57.63M, providing ample flexibility for dividends, buybacks, or growth.

$57.63M

FCF Per Share

Each share generates $0.46 in free cash annually.

$0.46

FCF Yield

ARQT converts 1.71% of its market value into free cash.

1.71%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

118.13

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.03

vs 25 benchmark

P/B Ratio

Price to book value ratio

14.76

vs 25 benchmark

P/S Ratio

Price to sales ratio

6.83

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.47

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.92

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.14

vs 25 benchmark

ROA

Return on assets percentage

0.06

vs 25 benchmark

ROCE

Return on capital employed

0.10

vs 25 benchmark

How ARQT Stacks Against Its Sector Peers

MetricARQT ValueSector AveragePerformance
P/E Ratio118.1331.16 Worse (Expensive)
ROE14.18%563.00% Weak
Net Margin5.88%5556.00% Weak
Debt/Equity0.470.09 Weak (High Leverage)
Current Ratio2.925.60 Strong Liquidity
ROA5.70%-17608.00% (disorted) Weak

ARQT outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Arcutis Biotherapeutics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

0.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

96.66%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

98.60%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ